Brainreader A/S

Based in Denmark, Brainreader A/S operates as a provider of advanced MRI analysis software, focusing on improving the early detection and assessment of neurodegenerative diseases through innovative technology. Brainreader A/S specializes in the development of medical imaging software, particularly Neuroreader®, which enhances the analysis of MRI scans. Founded in 2011 in Aalborg, Denmark, the company has secured DKK 49 million in funding from investors including Dahlgren Capital and Investo Capital. The latest funding round occurred on May 28, 2025, and supports their growth initiatives.

CEO Mads Fiig leads the company, bringing significant expertise to its operations. Brainreader A/S primarily offers its flagship product, Neuroreader®, an advanced MRI volumetric analysis software specifically designed to enhance the early detection of neurodegenerative diseases. This FDA-cleared and CE-marked medical device effectively analyzes MRI scans to identify abnormal brain patterns, significantly reducing the time traditionally required for manual segmentation. Neuroreader® quantifies 45 critical brain structures within approximately 10 minutes, providing healthcare professionals with timely assessments that could improve patient outcomes.

The solutions are targeted at MRI facilities, hospitals, and research institutions, serving a diverse clientele that includes neurologists and radiologists across North America and Europe. In 2023, Brainreader A/S reported an EBITDA of -DKK 999,246. 9. The company generates revenue through a business model involving direct sales and subscription services for its Neuroreader® software, collaborating with healthcare providers and institutions.

Clients typically engage through licensing agreements, allowing seamless integration of Neuroreader® into existing workflows. While specific pricing plans are not publicly disclosed, the product is positioned to deliver substantial diagnostic value to its users, supporting a competitive pricing strategy within the healthcare technology sector. In May 2025, Brainreader A/S raised DKK 49 million in venture funding led by Dahlgren Capital, with participation from Investo Capital. The company intends to utilize this funding to enhance research and development efforts, support the launch of Neuroreader®, and scale its commercial operations, particularly targeting the US market.

This strategic investment aims to expand Brainreader's footprint in the medical imaging sector, facilitating the introduction of innovative products and increasing market penetration.